Holen Sie sich die Stockscreener-App
96.45
1.33%
1.27
Schlusskurs vom Vortag:
$95.18
Offen:
$95.06
24-Stunden-Volumen:
1.96M
Relative Volume:
0.89
Marktkapitalisierung:
$19.11B
Einnahmen:
$8.01B
Nettoeinkommen (Verlust:
$807.20M
KGV:
23.87
EPS:
4.0411
Netto-Cashflow:
$1.13B
1W Leistung:
+7.27%
1M Leistung:
+9.18%
6M Leistung:
-6.56%
1J Leistung:
-3.46%
1-Tages-Spanne:
$95.06
$97.00
1-Wochen-Bereich:
$87.37
$97.22
52-Wochen-Spanne:
$84.59
$114.44
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Firmenname
Zimmer Biomet Holdings Inc
Sektor
Branche
Telefon
(574) 267-6131
Adresse
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
96.45 | 18.86B | 8.01B | 807.20M | 1.13B | 4.0411 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Herabstufung | Goldman | Neutral → Sell |
| 2026-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2026-01-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-11-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-09-18 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-07-15 | Hochstufung | Roth Capital | Neutral → Buy |
| 2024-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-10 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-21 | Hochstufung | Argus | Hold → Buy |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-10-20 | Eingeleitet | ROTH MKM | Neutral |
| 2023-08-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-05-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-03-29 | Eingeleitet | UBS | Sell |
| 2023-03-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-01-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Underweight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-04-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-03-02 | Herabstufung | Loop Capital | Buy → Hold |
| 2022-02-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-08 | Bestätigt | Citigroup | Buy |
| 2022-02-08 | Bestätigt | Deutsche Bank | Hold |
| 2022-02-08 | Bestätigt | JMP Securities | Mkt Outperform |
| 2022-02-08 | Bestätigt | JP Morgan | Neutral |
| 2022-02-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-08 | Bestätigt | Stifel | Buy |
| 2022-02-08 | Bestätigt | Truist | Buy |
| 2022-02-08 | Bestätigt | UBS | Neutral |
| 2022-02-08 | Bestätigt | Wells Fargo | Underweight |
| 2022-02-02 | Herabstufung | UBS | Buy → Neutral |
| 2022-01-19 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-12-09 | Herabstufung | Needham | Strong Buy → Buy |
| 2021-12-07 | Eingeleitet | Loop Capital | Buy |
| 2021-11-23 | Herabstufung | Argus | Buy → Hold |
| 2021-09-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-09 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-18 | Bestätigt | Needham | Strong Buy |
| 2020-10-20 | Eingeleitet | Northland Capital | Market Perform |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-08-05 | Bestätigt | Needham | Strong Buy |
| 2020-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-04-07 | Bestätigt | Needham | Strong Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-07 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2020-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2019-12-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-10-07 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-09-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-08-12 | Hochstufung | Argus | Hold → Buy |
| 2019-07-30 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-06-11 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2019-04-24 | Hochstufung | Needham | Buy → Strong Buy |
Alle ansehen
Zimmer Biomet Holdings Inc Aktie (ZBH) Neueste Nachrichten
Update Report: Is Zimmer Biomet Holdings Inc stock a value trap2025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
Why Zimmer Biomet Holdings Inc. stock is favored by hedge funds2025 Stock Rankings & Accurate Buy Signal Alerts - mfd.ru
ZBH.SW Zimmer Biomet (SIX) at CHF67.50 pre-market on volume spike: Feb 2026 outlook - Meyka
Market Participants Recognise Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Earnings - 富途牛牛
Skylands Capital LLC Sells 20,100 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Sound Shore Management Inc CT Decreases Stake in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Johnson Investment Counsel Inc. Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Envestnet Asset Management Inc. Grows Stock Position in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet Expects Paragon 28 To Power Double Digit Rise In 2026 - Citeline News & Insights
Zimmer Biomet Holdings Inc (ZBH) Q4 2025 Earnings Call Highlight - GuruFocus
Zimmer Biomet (NYSE:ZBH) Beats Estimates, Lifts Russell 1000 Healthcare - Kalkine Media
Zimmer Biomet (ZBH) Is Up 6.1% After Earnings Beat And New Buyback Plan Is Announced - Yahoo Finance
Citigroup Raises Price Target for Zimmer Biomet Holdings (ZBH) | ZBH Stock News - GuruFocus
Wells Fargo Raises Zimmer Biomet Holdings (ZBH) Price Target to $98 | ZBH Stock News - GuruFocus
Wells Fargo & Company Forecasts Strong Price Appreciation for Zimmer Biomet (NYSE:ZBH) Stock - MarketBeat
UBS Adjusts Price Target on Zimmer Biomet Holdings to $89 From $86, Maintains Sell Rating - marketscreener.com
Rothschild & Co Redburn Adjusts Zimmer Biomet PT to $115 From $125, Maintains Buy Rating - marketscreener.com
Barclays Adjusts Zimmer Biomet PT to $100 From $104, Maintains Underweight Rating - marketscreener.com
ZBH Q4 Deep Dive: U.S. Salesforce Overhaul Drives Guidance Caution Amid Product Momentum - Finviz
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2025 earnings call transcript - MSN
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2025 Earnings Call Transcript - Insider Monkey
Zimmer plans US salesforce reorganization - Yahoo Finance
Zimmer Biomet Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Zimmer Biomet (ZBH) Margin Compression And One Off Loss Test Bullish Growth Narrative - Sahm
Zimmer Biomet shares climb after fourth-quarter sales and earnings growth - AlphaStreet News
Zimmer Biomet Q4 Earnings Call Highlights - MarketBeat
Zimmer Biomet outlines 2026 revenue growth of 1%–3% amid US sales force overhaul and innovation cycle - MSN
Zimmer Biomet earnings beat Wall Street expectations - The Journal Gazette
BTIG Reiterates Buy Rating on Zimmer Biomet (ZBH) with $112 PT | - GuruFocus
Zimmer Biomet (NYSE:ZBH) Earns Hold Rating from Needham & Company LLC - MarketBeat
BTIG Research Reiterates Buy Rating for Zimmer Biomet (NYSE:ZBH) - MarketBeat
Citigroup Raises Price Target on Zimmer Biomet to $98 From $94, Maintains Neutral Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Zimmer Biomet to $98 From $93 - marketscreener.com
Zimmer Biomet beats quarterly estimates on strong implant demand amid US sales overhaul - marketscreener.com
Zimmer Biomet reports 2025 revenue growth yet tempers 2026 outlook - Yahoo Finance
Zimmer Biomet posts Q4 beats, sets 2026 guidance - MassDevice
Zimmer Biomet (ZBH) Exceeds Q4 Expectations with Strong Orthoped - GuruFocus
Zimmer Biomet Holdings, Inc. announces an Equity Buyback for $1,500 million worth of its shares. - marketscreener.com
Tranche Update on Zimmer Biomet Holdings, Inc.'s Equity Buyback Plan announced on May 29, 2024. - marketscreener.com
Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
Zimmer Biomet (NYSE:ZBH) Beats Q4 CY2025 Sales Expectations - Finviz
Zimmer Biomet Q4 2025 Earnings & 2026 Financial ForecastNews and Statistics - IndexBox
Zimmer Biomet (NYSE:ZBH) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance - MSN
Zimmer Biomet beats quarterly estimates on strong hips, knees device demand - marketscreener.com
Zimmer Biomet (NYSE:ZBH) Releases FY 2026 Earnings Guidance - MarketBeat
Zimmer Biomet (ZBH) Announces $1.5 Billion Stock Buyback Plan - GuruFocus
Zimmer Biomet (ZBH) Projects Revenue Growth for Fiscal Year 2026 - GuruFocus
Zimmer Biomet (ZBH) Reports Strong Q4 Revenue and Strategic Adva - GuruFocus
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Zimmer Biomet (ZBH) Q4 Earnings Surpass Expectations, Announces Buyback Plan - GuruFocus
Finanzdaten der Zimmer Biomet Holdings Inc-Aktie (ZBH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.69%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):